Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Safety Study of Bifeprunox Investigating Flexible Doses of 20, 30, or 40mg/Day in Patients With Schizophrenia Who Have Completed Studies 10206 or 10265

NCT00861497 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT00861497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00861497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Safety Study of Bifeprunox Investigating Flexible Doses of 20, 30, or 40mg/Day in Patients With Schizophrenia Who Have Completed Studies 10206 or 10265
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2006
Completion date
July 31, 2009
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia